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Doxorubicin (DOXO) treatment is limited by its cardiotoxicity, since it causes cardiac-progenitor-cell depletion. Although the
cardioprotective role of the stromal cell-derived factor-1/C-X-C chemokine receptor type 4 (SDF1/CXCR4) axis is well established,
its involvement during DOXO-induced cardiotoxicity has never been investigated. We showed that in a mouse model of DOXO-
induced cardiomyopathy, CXCR4+ cells were increased in response to DOXO, mainly in human cardiac mesenchymal progenitor
cells (CmPC), a subpopulation with regenerative potential. Our in vitro results showed a CXCR4 induction after 24 h of DOXO
exposure in CmPC. SDF1 administration protected from DOXO-induced cell death and promoted CmPC migration. CXCR4
promoter analysis revealed zinc finger E-box binding homeobox 1 (ZEB1) binding sites. Upon DOXO treatment, ZEB1 binding
decreased and RNA-polymerase-II increased, suggesting a DOXO-mediated transcriptional increase in CXCR4. Indeed, DOXO
induced the upregulation of miR-200c, that directly targets ZEB1. SDF1 administration in DOXO-treated mice partially reverted the
adverse remodeling, decreasing left ventricular (LV) end diastolic volume, LV ejection fraction and LV anterior wall thickness in
diastole, recovering LV end systolic pressure and reducing± dP/dt. Moreover, in vivo administration of SDF1 partially reverted
DOXO-induced miR-200c and p53 protein upregulation in mouse hearts. In addition, downmodulation of ZEB1 mRNA and protein
by DOXO was significantly increased by SDF1. In keeping, p21 mRNA, that is induced by p53 and inhibited by ZEB1, is induced by
DOXO treatment and is decreased by SDF1 administration. This study showed new players of the DOXO-induced cardiotoxicity,
that can be exploited to ameliorate DOXO-associated cardiomyopathy.
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Anthracyclines are effective chemotherapeutic agents.
Among them, Doxorubicin (DOXO) is largely used in different
types of tumors, including breast cancer, esophageal carci-
noma, osteosarcoma, sarcomas and lymphomas.1 Unfortu-
nately, the clinical application of DOXO is limited by cumulative
dose-dependent cardiotoxicity.1 In particular, DOXO-induced
cardiotoxicity determines progressive cardiac dilation, con-
tractile dysfunction and ultimately congestive heart failure.2
Studies in experimental animal models and human endomyo-
cardial biopsies evidenced histological alterations associated
to DOXO-induced cardiomyopathy, consisting of multiple
areas of interstitial fibrosis that replace apoptotic and necrotic
cardiomyocytes.2,3 Oxidative stress and DNA damage are
considered the key mechanisms involved in DOXO-mediated
cardiotoxicity.4,5
Although cardiomyocytes have been considered the most
representative cellular targets, other cells, including endo-
thelial cells (EC)6 and progenitor cells, are involved in DOXO-
induced cardiomyopathy.7,8 Indeed, DOXO, similarly to
other anticancer drugs, such as Trastuzumab and Sorafenib,
has been demonstrated to affect the survival and function
of cardiac mesenchymal progenitor cells (CmPC), leading to
a progressive loss of cardiac tissue homeostasis and even-
tually to congestive heart failure.9–13 The stromal cell-derived
factor-1/C-X-C chemokine receptor type 4 (SDF1/CXCR4)
axis is involved in many pathological conditions of tissue injury
and stress, including cardiovascular diseases and myocardial
infarction. After an ischemic insult, SDF1 acts as a chemoat-
tractant to stimulate the homing of circulating CXCR4-positive
cells, as well as of other stem cells, to the site of injury, for
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tissue regeneration and repair. In particular, SDF1 provides
trophic support for cells, stimulates progenitor cell differentia-
tion and promotes angiogenesis through a paracrine
mechanism.14 Indeed, the activation of the SDF1/CXCR4
axis promotes extensive mobilization of CmPC and supports
cardiac repair of the infarcted heart.15–17 Notably, the cardiac
protective role of this axis has been recently confirmed in a
clinical setting of ischemic heart failure.18 Moreover, in dilated
cardiomyopathy, SDF1 increases and enhances the number
of circulating progenitor cells19 and DOXO-induced cardio-
myopathy promotes mesenchymal stem cell migration to the
heart, where SDF1 expression is elevated.20
MicroRNAs (miRNAs) are 21–23 nucleotides RNA mole-
cules that regulate the stability or translational efficiency of
target messenger RNAs.21 miRNAs control a wide range of
cell functions and have been associated with inflammation,
oxidative stress and different pathologies, including heart
failure, cardiac hypertrophy and myocardial arrhythmias.22,23
Indeed, our group demonstrated that the entire miR-200 family
is upregulated in endothelial cells upon oxidative stress.24
In particular, we demonstrated that miR-200c is the most
upregulated family member in EC upon exposure to oxidative
stress and that its increase is responsible for apoptosis and
senescence via the inhibition of miR-200 family target zinc
finger E-box binding homeobox 1 (ZEB1).24
In this paper, we showed that DOXO induces the in vitro and
in vivo upregulation of CXCR4, making human CmPC more
prone to respond to SDF1 stimulation. Moreover, we demon-
strated that DOXO-induced CXCR4 upregulation in CmPC is
mediated, at least in part, by a miR-200c/ZEB1 pathway. As a
consequence, the activation of SDF1/CXCR4 axis promotes
CmPC migration and improves cell survival upon DOXO
treatment. Finally, the activation of the SDF1/CXCR4 axis
ameliorates cardiac functional deficits in mice treated with
cardiotoxic doses of DOXO via a miR-200c/ ZEB1/p53
pathway modulation.
Results
Doxorubicin increases CXCR4 expression in vivo and
in vitro. To dissect the mechanism by which SDF1 exerts its
cardioprotective properties, the expression levels of the most
characterized receptor CXCR4 was assessed in heart
sections of DOXO-treated and untreated mice. Interestingly,
the total number of CXCR4+ cells was significantly increased
in response to 21 days of DOXO treatment (Figure 1a and
Supplementary Fig S1a). Immunofluorescence analysis
revealed that CXCR4 receptor was mainly upregulated
in cells localized in the interstitial space between cardio-
myocytes and CmPC, identified by the expression of the
mesenchymal markers CD44 and CD29 (Figure 1b,Supple-
mentary Fig S1b).25,26 To further confirm these results
in vitro, we characterized by flow cytometry CmPC treated
or not with 1 μM DOXO for 24 h (h). Results revealed that
Figure 1 CXCR4 is increased in vivo in response to DOXO. (a) CXCR4+ cell quantitative analysis. The number of CXCR4+ cells from 9 randomly selected fields was counted
for each tissue section of DOXO and untreated mice (CTR). The CXCR4+ cells were calculated as a percentage on the total number of nuclei in the same fields (9 different fields
per mouse). The number of CXCR4+ cells were significantly higher in DOXO compared to CTR mice (**Po0.005). Data were representative of five independent experiments.
Results are presented as mean±S.E.M. (b) Representative images of heart sections of CTR and DOXO mice, immunostained with CXCR4 (green) and CD44 (red) antibody.
Nuclei are stained with Hoechst 33258 (blue). Scale bar: 20 μm and 50 μm in the inset
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CmPC fully express CD44, CD29, CD73 and CD166 surface
markers, confirming their mesenchymal cell origin. Moreover,
we confirmed that after DOXO treatment the percentage of
CXCR4+ cells increased (Supplementary Fig S2).
To assess the effect of DOXO in human CmPC, CXCR4
expression was measured in CmPC treated with 1 μM DOXO
for 24 h. Interestingly, both the mRNA (Figure 2a) and protein
levels of CXCR4 were significantly upregulated (Figures 2b
and c).
SDF1 induces migration and protects DOXO-treated
CmPC from apoptosis. To assess the relationship and
timing between DOXO-treatment and cell death, we per-
formed a DOXO treatment time course followed by cell death
analysis in CmPC (6, 24 and 48 h). We observed a signifi-
cant induction of cell death after 48 h of DOXO treatment
(Figure 3a). Successively, to address the role of SDF1 on cell
survival, human CmPC were treated with DOXO for 24 h.
Afterwards, DOXO was removed and human CmPC were
kept for an additional 24 h in medium supplemented with
SDF1 or medium alone. As expected, DOXO-induced cell
death and SDF1 decreased the cell death index by 23%± 9
Figure 2 CXCR4 is induced in response to DOXO in CmPC. (a) qPCR analysis
showing CXCR4 upregulation in CmPC treated with 1 μM DOXO for 24 h as
compared to untreated cells (n= 3, *Po0.05) Results are presented as mean±
S.D.; (b) Representative western blot showing an increase in CXCR4 expression in
CmPC upon DOXO treatment. β-actin was used as a loading control. Actin indicate
β-actin; (c) Expression levels of CXCR4 protein were evaluated by densitometric
analysis and normalized by α-tubulin protein levels (n= 3, *Po0.05)
Figure 3 SDF1 protects and induces migration of DOXO treated CmPC. (a) Cell
death analysis of CmPC upon DOXO treatment for increasing periods of time starting
from 6 h up to 48 h as indicated. Cell death increased significantly 48 h after DOXO
treatment (n= 4, ***Po0.001). (b) Cell death analysis of CmPC exposed or not to
1 μM DOXO. DOXO was added to CmPC for 24 h and then removed. SDF1,
AMD3100 and α-CXCR4 were added after 24 h at the following dosages: SDF-1 at
100 ng/ml, AMD3100 at 3.2 μg/ml and α-CXCR4 at 10 μg/ml. Cell death was
determined at 48 h. Mean values± SEM of three independent experiments run in
triplicate (*Po0.05; ***Po0.0001). (c) Chemotatic responses of CmPC exposed or
not to 1 μM DOXO for 24 h in response to 100 ng/ml SDF1 or 10% FBS. Migration
efficiency of CmPC was estimated using a Transwell assay. After 16 h of incubation
transmigrated cells were quantified using crystal violet. The results are expressed as
fold change of the untreated control cells exposed or not to DOXO. DOXO—cells
treated with 1 μM DOXO for 24 h; AMD3100—serum starved CmPC treated
AMD3100 25 μg/ml during migration; DOXO+AMD3100—cells treated with 1 μM
DOXO for 24 h and AMD3100 25 μg/ml during migration (n= 6, *Po0.05;
**Po0.005; ***Po0.0001)
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(Po0.01). Importantly, the SDF1 protective effect was signifi-
cantly reverted by the addition of the CXCR4-specific
antagonist AMD3100 (Po0.05), as well as the specific
CXCR4 blocking antibody27 (Po0.05; Figure 3b). To deter-
mine whether the SDF1/CXCR4 pathway was functional,
human CmPC were treated or not with DOXO for 24 h and,
successively, migration was stimulated with SDF1 for 16 h.
Treatment with fetal bovine serum (FBS) was used as a
positive experimental control. Intriguingly, we found that
SDF1-mediated migration was significantly increased in
CmPC treated with DOXO. As expected, SDF1-induced
migration was significantly inhibited by the CXCR4 selective
antagonist AMD310028 only after DOXO treatment. Indeed,
AMD3100 did not exert any effect upon SDF1 treatment
since CmPC do not express CXCR4 in absence of DOXO
(Figure 3c). This result demonstrated that human CmPC
migration was specifically mediated by the activation of
SDF1/CXCR4 axis (Figure 3c). Taken together, these results
demonstrated that the SDF1/CXCR4 axis was functionally
coupled to downstream signaling in CmPC.
Doxorubicin modulates miR-200c/ZEB1 pathway in
CmPC. Since DOXO cardiotoxicity has been ascribed to
oxidative stress and DNA damage, we tested the possibility
that DOXO could affect the expression of miR-200c and its
target protein ZEB1, that our group demonstrated to be
modulated by oxidative stress and to stimulate apoptosis and
senescence of HUVECs via the upregulation of miR-200c
and the downregulation of ZEB1.24
We found that miR-200c was upregulated after 24 h of
DOXO treatment (Figure 4a). Conversely, the mRNA level of
the miR-200c target ZEB1 was downregulated (Figure 4b).
We have previously demonstrated that p53 is necessary for
miR-200c upregulation by oxidative stress in EC24 and DOXO
treatment is known to induce p53 and oxidative stress;29 in
keeping, we found that ZEB1 protein was downregulated 24 h
after DOXO treatment, a time point at which p53 protein
expression was upregulated (Figures 4c and d).
ZEB1 inhibits CXCR4 expression. As a further confirma-
tion of the inhibitory role of ZEB1 on CXCR4 expression, we
knocked-down ZEB1 expression using a specific shRNA
sequence (Figures 5a and b). We found that ZEB1 knock-
down provoked CXCR4 mRNA upregulation (Figure 5c).
Moreover, ZEB1 knockdown increased CXCR4 protein
expression on the cell surface of CmPC both in the absence
(Figure 5d upper and bottom left panels) and following DOXO
exposure, when the DOXO-induced CXCR4 increase was
further enhanced by ZEB1 depletion (Figure 5d upper and
bottom right panels).
These data further confirm that ZEB1 represses CXCR4
expression in CmPC.
ZEB1 binds to the promoter and the intronic region of the
CXCR4 gene. ZEB1 is a transcription factor that binds to
E-box sites which usually act as an inhibitor of target genes
transcription.30 Therefore, we evaluated whether the CXCR4
gene could be a possible ZEB1 transcriptional target.
Examination of 2.1 kbof CXCR4 human promoter and its
intronic region revealed the existence of five E-box sites at
positions − 2029 bp, −1644 bp, − 983 bp, −554 bp, −262 bp
upstream of the first exon and four in the intronic region at
positions +881 bp, +916 bp, +1238 bp, +1454 bp (Figure 6a).
Interestingly, comparison of the human, mouse, rat, rabbit, bos
taurus and pan troglodytes CXCR4 regions, encompassing
the ZEB1 consensus sites, revealed that the E-boxes at
+881 bp and +916 bp are highly conserved across species,
suggesting the functional importance of these intronic
sequences for CXCR4 expression (Figure 6b). Site-specific
Chromatin immunoprecipitation (Chip) experiments followed
Figure 4 DOXO treatment upregulates miR-200c and downregulates ZEB1. (a) miR-200c expression upon 24 h DOXO treatment. miR-200c was significantly induced by
DOXO treatment (n= 4, *Po0.05). Results are presented as mean±S.E.M. (b) ZEB1 mRNA expression was quantified by qPCR; ZEB1 mRNA decreased upon DOXO
treatment at 24 h (n= 4, **Po0.01). Results are presented as mean±S.E.M. (c) CmPC were treated with 1 μM DOXO for 24 h. ZEB1 and p53 proteins were evaluated by
Western blot analysis. A representative western blot showing DOXO treatment induced p53 protein expression and ZEB1 downregulation. β-actin was used as a loading control.
Actin indicates β-actin (d) Expression levels of ZEB1 and p53 protein were evaluated by densitometric analysis and normalized by β-actin protein levels (n= 3, *Po0.05)
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by quantitative real-time PCR (ChIP-qPCR) indicated,
although to different extents, a recruitment of ZEB1 and Pol
II to the promoter region up to −2097 bp upstream of the first
exon and in the intronic region encompassing from +735 to
+1552 bp (Figures 6c and d).
In order to verify whether the increased expression of
CXCR4 observed upon DOXO treatment was associated with
a decrease of the binding activity of ZEB1 to the CXCR4
promoter, we performed ChIPexperiments in cells treated with
1 μM DOXO for 24 h. Results showed that ZEB1 occupancy
was consistently reduced after DOXO treatment both in the
promoter region encompassing the − 2097 bp to −1572 bp
upstream of the first exon and in the intronic E-boxes from
+735 to +1552 bp. ZEB1 recruitment was still inhibited, but not
significantly, in the promoter region encompassing −1029 bp
to −210 bp (Figure 6c). Interestingly, Pol II binding to the
proximal promoter region was increased after DOXO treat-
ment both in the promoter sequence, although not signifi-
cantly, and significantly in the intronic region, suggesting a
higher CXCR4 promoter activity upon DOXO treatment
(Figure 6d). These data indicate a role of ZEB1 as a
transcriptional repressor of CXCR4 expression and its
involvement in cellular response to DOXO treatment.
SDF1 partially rescues cardiac dysfunction induced by
doxorubicin. The administration of SDF1 has been shown to
promote cardioprotection in both animal models and in
humans.31 Therefore, we examined whether SDF1 exhibited a
cardioprotective action in DOXO-treated mice. SDF1 was
administrated in a mouse model of DOXO-induced cardiotoxi-
city recently established in our laboratory32 (details are reported
in the Materials and Methods Section and Supplementary Fig
S3a). Left ventricular (LV) function was measured by transthor-
acic echocardiography before and 3 weeks after DOXO alone or
DOXO+SDF1 or saline. No differences were found among
groups before drug treatment (Figures 7a–d).
At day 21, LV dysfunction was greater in DOXO-treated
mice with respect to the control group, as shown by a
significant increase in LV end systolic volume (LVESV), LV
end diastolic volume (LVEDV) and by a reduction in LVejection
fraction (LVEF) and LV anterior wall thickness at diastole
(LVAWd; Figures 7a–d), in accordance with previous findings
of our group.32
Notably, DOXO+SDF1 treatment reverted LV dysfunction at
day 21, as evidenced by a significant decrease of both LVESV
(Figure. 7a; Po0.05) and LVEDV (Figure 7b; Po0.001) and
increase of LVAWd (Figure. 7d; Po0.05) versus DOXO-
treated mice. In contrast, DOXO+SDF1-induced slight but not
significant increase in LVEF (Figure 7c). Similar results were
obtained by invasive measurements with a Millar catheter.
As shown by a significant reduction of LV systolic pressure
(LVSP; Figure 7e) and±dP/dt (Figure 7f), DOXO treatment
impaired both LV contractility and relaxation with respect to
controls. Accordingly, DOXO+SDF1 treatment significantly
recovered these parameters with respect to DOXO-treated
mice (Figures 7e and f).
Figure 5 ZEB1 knockdown elicits CXCR4 increase. CmPC were infected either with the lentivirus carrying ZEB1-specific shRNA or with the control virus. After 24 h, cells
were selected with puromycin. (a) Representative western blot demonstrating a 60% knockdown of ZEB1 expression in CmPC infected with a lentivirus encoding a ZEB1-specific
shRNA sequence. (b) Expression levels of ZEB1 protein were evaluated by densitometric analysis and normalized by β-actin protein levels (n= 3, *Po0.02). (c) CmPC
transduced with a ZEB1-specific shRNA showed an upregulation of CXCR4 mRNA compared with control. (d) CmPC transduced with a ZEB1-specific shRNA displayed CXCR4
protein expression on the cell surface of CmPC, and increased both in absence of DOXO (upper and bottom left panels) and in presence of DOXO (upper and bottom right panels)
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SDF1 partially rescues DOXO-dependent cardiac dys-
function via a miR-200c/ ZEB1/p53 pathway modulation.
We successively asked whether SDF1 cardioprotection was
due to the modulation of miR-200c/ZEB1/p53 pathway.
To this end, we evaluated miR-200c in LV heart extracts of
mice treated with DOXO and we found that miR-200c
expression levels were significantly increased compared to
saline-treated mice (Figure 8a). Interestingly, SDF1 treatment
uponDOXO significantly reducedmiR-200c levels (Figure 8a).
Moreover, we tested themRNA expression levels of ZEB1 and
we observed that, inversely to miR-200c, ZEB1 mRNA was
downregulated by DOXO and returned to control levels in
DOXO+SDF1-treated mice (Figure 8b). We confirmed by
western blot analysis of the same specimens that ZEB1
protein, as well, is downregulated by DOXO and increased in
DOXO+SDF1-treated hearts (Figures 8c and d).
We also tested p53 mRNA expression levels and we did not
find a significant modulation upon DOXO or DOXO+SDF1
treatment (Figure 8b). On the other end p53 protein is induced
by DOXO and decreased in DOXO+SDF1 treated extracts
(Figures 8c and d).
In addition, we evaluated the mRNA of the CDK inhibitor
p21Waf1/Cip1/Sdi1 (p21) expression levels, which is a direct
transcriptional target of p5333 and ZEB1 (known to inhibit
transcriptionally p21).34 In keeping, we found an upregulation
of p21 mRNA in DOXO treated mice and a significant
decrease in DOXO+SDF1 treated hearts (Figure 8b).
Discussion
The cardioprotective role of the SDF1/CXCR4 axis was
already established in myocardial infarction,35–38 however, it
was never studied in DOXO-induced cardiotoxicity.
The effect of DOXO administration has beenmainly focused
on its toxic effects on breast cancer cells. However, according
to the most recent literature,11,13 our results indicated that
DOXO treatment markedly affects the pool of cardiac resident
progenitors, including CmPC. At the molecular level, we
observed that DOXO induces the upregulation of CXCR4,
making human CmPC more prone to respond to SDF1
stimulation. Indeed, we demonstrated that the administration
of SDF1 is able to protect CmPC from DOXO-induced cell
death and to induce their migration, demonstrating that the
SDF1/CXCR4 axis is functionally coupled to downstream
signaling.
Moreover, we demonstrated a novel implication of miR-
-200c/ZEB1 pathway in response to DOXO. We have
previously showed that p53 is necessary for miR-200c
Figure 6 CXCR4 is a ZEB1 target gene. (a) Schematic figure showing the E-box binding sites of ZEB1 in the promoter and in the intronic region of the human CXCR4 gene.
Five E-box sites are present at position – 2029 bp,− 1644 bp,− 983 bp,− 554 bp,− 262 bp upstream the first exon and four in the intronic region, at position +881 bp, +916 bp,
+1238 bp, +1454 bp. (b) ZEB1 consensus sites revealed that the E-box sites at +881 bp and +916 bp are highly conserved across species of humans, mice, rats, rabbits, bos
taurus and pan troglodytes. (c) ChIP assay of CmPC in the absence or presence of 1 μM DOXO treatment for 24 h was performed with a ZEB1 antibody, followed by quantitative
real-time PCR (ChIP-qPCR), using specific primers encompassing ZEB1 consensus sequences. (d) ChIP-qPCR CmPC in the absence or presence of 1 μM DOXO treatment for
24 h was performed with a Pol II-specific antibody
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upregulation by oxidative stress in EC.24 Since DOXO is
known to induce p53 and oxidative stress,29 the upregulation
of miR-200c was expected.
Further, our results proved that miR-200c upregulation and
the concomitant inhibition of its target ZEB1 is implicated in the
increased expression of CXCR4.
As amatter of fact, ZEB1 is a transcriptional inhibitor and we
here showed that ZEB1 binds both to the promoter and to the
intronic sequence (the region upstream of the first exon),
inhibiting CXCR4 transcription.
This intronic sequence has been demonstrated to play an
important regulatory role for CXCR4 expression in different
papers,39,40 and for this reason we tested also this gene
sequence for ZEB1 binding. Moreover, in this region we found
two E-boxes highly conserved across species, suggesting the
functional importance of these intronic sequences for CXCR4
regulation.
Interestingly, upon DOXO treatment, ZEB1 binding on the
CXCR4 promoter and intronic sequence decreased and Pol II
binding to the proximal promoter region increased both in the
promoter sequence and in the intronic region, suggesting a
higher CXCR4 promoter activity upon DOXO treatment.
In keeping with this, the upregulation of CXCR4 by the
miR-200 family was already reported in mouse embryonic
Figure 7 SDF1 partially rescues cardiac dysfunction induced by DOXO. Echocardiographic examination was performed on mice before (Day 0) and 21 days after the
administration of DOXO (n= 13), DOXO+SDF1 (n= 13) or saline (n= 13); (a) LV end-systolic volume (LVESV), (b) LV end-diastolic volume (LVEDV), (c) LV ejection fraction
(LVEF), (d) LVanterior wall thickness at diastole (LVAWd). Evaluation of LV hemodynamic function with a Millar micro-tip catheter was performed at day 21; (e) LV systolic pressure
(LVSP), (f) maximal rate of pressure development (+dP/dt) and maximal rate of pressure relaxation (-dP/dt). Saline, n= 10; DOXO, n= 10; DOXO+SDF1, n= 13. Results are
presented as mean±SD. (*Po0.05; **Po0.01; ***Po0.001)
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stem cells upon nitric oxide treatment.41 In this study the
mechanism of CXCR4 upregulation involved another tran-
scription factor targeted by the miR-200 family that is Zinc-
Finger-E-Box-Binding-Homeobox-2 (ZEB2), which also binds
to and inhibits E-boxes.41
Notwithstanding acute upregulation of miR-200c ultimately
leads to CXCR4 upregulation and consequent SDF1-induced
amelioration of cardiotoxicity, chronic upregulation of
miR-200c might be one of the leading causes for the
establishment of DOXO-induced apoptosis and senescence.
In fact, we previously demonstrated that oxidative stress
inducing miR-200c causes ZEB1 downregulation which
enhances apoptosis and senescence in EC and in different
cell types.24 Recently, we demonstrated that miR-200c
upregulation is responsible of reactive oxygen species
production and nitric oxide decrease by targeting three
important proteins involved in endothelial function (i.e.,
Sirtuin1, endothelial nitric oxide synthase and Forkhead box
O1), further supporting a role for this miRNA in cardiotoxicity.42
Notably, CXCR4 upregulation preceded DOXO-induced cell
death, therefore, if the time frame of SDF1 administration is
precocious, it can prevent the negative effects caused by
anthracyclines.
In the present study, we demonstrated for the first time, that
in vivo administration of SDF1 attenuates DOXO-induced LV
remodeling and functional impairment producing a significant
recovery of LVSP and±dP/dt reduction when compared to
DOXO-treated mice.
Moreover, our results indicated that in LV specimens of mice
treated with SDF1+DOXO there is a decrease of miR-200c
and p53 upregulation caused by DOXO and a restoration of
ZEB1 expression, explaining SDF1 positive effect also via the
modulation of this molecular pathway. In keeping, p21 mRNA,
that is induced by p5333 and inhibited by ZEB1,34 is induced by
DOXO treatment and is decreased by SDF1 administration
(Supplementary Fig. S4).
Cumulatively, our study provided the first evidence that: (1)
DOXO promotes a compensatory response in human CmPC
by the CXCR4 upregulation, making this cardiac mesen-
chymal subpopulation more prone to respond to SDF1
protective stimuli; (2) DOXO induces the upregulation of
miR-200c which, in turn, downregulates ZEB1; 3) ZEB1 binds
Figure 8 SDF1 partially rescues DOXO-dependent cardiac dysfunction via a miR-200c/ZEB1/p53 pathway modulation. Mice were treated with DOXO, DOXO+SDF1 or saline
for 21 days. (a) Then mRNA was extracted from LV and analyzed for miR-200c, p53, ZEB1 and p21 mRNA expression levels. p53 mRNA was not modulated either by DOXO or
DOXO+SDF1. miR-200c, and p21 mRNA were induced by DOXO and were all significantly decreased by SDF1 treatment. ZEB1 mRNA was downregulated by DOXO and
returned to control levels by SDF1 treatment (Saline, n= 5; DOXO, n= 5; DOXO+SDF1, n= 5; *Po0.05; **Po0.01; ***Po0.001). (b) Representative western blot with anti-p53
and ZEB1 antibodies showed that p53 upregulation by DOXO was decreased by SDF1 treatment and ZEB1 demise was reverted by SDF1 (Saline, n= 5; DOXO, n= 5; DOXO
+SDF1, n= 5). (c) Expression levels of p53 and ZEB1 protein were evaluated by densitometric analysis and normalized by β-actin protein levels (n= 5; *Po0.05; ***Po0.001)
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to the CXCR4 promoter repressing its expression (Supple-
mentary Fig. S4); (4) the activation of the SDF1/CXCR4 axis is
protective both in vivo and in vitro against the adverse cardiac
events induced byDOXO; (5) SDF1 treatment is able to rescue
cardiac dysfunction via a miR-200c/ ZEB1/p53 pathway
modulation.
Our study revealed new possible molecular mechanisms
associated with DOXO treatment that could allow the improve-
ment of current therapeutic approaches or the development
of novel strategies and hopefully lead to the increase in the
number of long-term survivors experiencing anticancer
therapy cardiotoxicity.
Materials and Methods
Ex-vivo immunofluorescence and confocal analysis. Experiments
were performed in accordance with the national and international law and policies
(4D.L. N.116, G.U., supplement 40, 18-2-1992; EEC Council Directive 86/609, OJ L
358,1,12-12-1987) and the guidelines indicated in the Declaration of Helsinki. The
protocol was approved by the University Committee on Animal Resources at the
University of Milan. All efforts were made to minimize animal suffering.
Female C57Bl/6 wild-type mice (CharlesRiver Laboratories, Italy) aged 8 to
10 weeks were randomly divided into two groups.32 The DOXO group (n= 7)
received six equal intraperitoneal DOXO injections over a period of 2 weeks (4 mg/kg
each; cumulative dose, 24 mg/kg). The control group (n= 7) was treated with
physiological saline in the same manner as the regimens for the DOXO group.
After imaging, mice were killed and weighed, then hearts were blocked in diastole
by intracardiac injection of 100 ml potassium chloride (3 mol/l). Mouse hearts were
fixed in 10% formalin and embedded in paraffin. For immunofluorescence analysis,
sections were deparaffinized, rehydrated, and boiled for 20 min in an antigen retrieval
buffer (sodium citrate, pH= 6.0, DAKO). Following antigen retrieval, sections were
incubated with primary antibody at 4 °C overnight. The following primary antibodies
were used: anti-CXCR4 (Abcam, Cambridge, UK), anti-CD44 (Abcam), anti-α-
sarcomeric actin (Sigma-Aldrich, Milan, Italy), and anti-CD29 (Abcam). After washing,
sections were incubated with the following fluorochrome-conjugated antibodies for 1 h
at room temperature in the dark: Alexa488 and Alexa546 (Invitrogen, Milan, Italy).
Nuclear staining was performed by incubating sections with Hoechst 33342 (Sigma-
Aldrich). Sections were observed using a Zeiss LSM 710 confocal microscope (Zeiss,
Milan, Italy). Images were acquired at × 40 magnification to count the CXCR4 or the
double-positive cells (CXCR4/CD44 and CXCR4/CD29). The CXCR4+ cells were
calculated as a percentage of the total number of nuclei in the same fields (nine
different fields per mouse). CXCR4/CD44+ cells were calculated as a percentage of
the total number of CD44+ cells in the same fields (three different fields per mouse,
data not shown).
CmPC isolation and culture. Right auricles were obtained from donors
undergoing cardiac surgery after Local Ethics Committee approval (protocol CCFM
C9/607) and signed informed consent in accordance with the Declaration of
Helsinki. CmPC were obtained by adapting two different methods previously
described.43,44
Western blot. Whole cell lysates were obtained by harvesting cells with
Laemmli buffer, containing 100 mM Tris (pH 6.8), 20% glycerol, 4% SDS. Protein
concentration was determined by BCA protein assay kit (Pierce) following the
manufacturer's instructions. Then, DTT (200 mM) was added and lysates were
boiled for 5 min. Proteins were separated in SDS polyacrylamide gels and
transferred to nitrocellulose by standard procedures. The following antibodies were
used to detect the proteins of interest: anti-CXCR4 (Ab-2074; Abcam, UK); anti-
ZEB1 (H-102; Santa Cruz Biotechnology, Heidelberg, Germany); anti- human p53
(Ab-6, DO-1 Oncogene Research Products); anti-murine p53 (Ab-1; Oncogene
Research Products, Boston, MA, USA); anti-actin (AC15; Sigma).
Quantitative reverse transcriptase–polymerase chain reaction.
Total RNA was purified from CmPC at passage 4 (P4) using Trizol reagent
(Invitrogen) according to the manufacturer’s instructions. miR-200c expression was
evaluated by quantitative reverse transcriptase-PCR (qRT-PCR) using single
TaqMan microRNA assays (Life Technologies, Milan, Italy), according to
manufacturer’s instructions. Retro-transcription of 5 ng of total RNA was conducted
using the TaqMan MicroRNA Reverse Transcription Kit (Life Technologies, Milan,
Italy), followed by amplification with specific primers on a 7900HT Fast Real-Time
PCR System (Life Technologies). Results were expressed as cycle threshold (Ct)
levels and normalized using miR-16 as a calibrator. mRNAs levels were analysed
using the SYBR-GREEN qPCR method (5 ng per assay, Qiagen) and quantified
with ABI Prism 7000 SDS (Applied Biosystems). Relative expression was calculated
using the comparative Ct method (2–ΔΔCt). mRNA expression was normalized for
Beta-2-microglobulin (B2M) levels.
The following primers were used for SYBR-GREEN Real-Time PCR:
humanZEB1:
forward:5′-GGGAGGAGCAGTGAAAGAGA-3′;
reverse: 5′-TTTCTTGCCCTTCCTTTCTG-3′;
humanB2M:
forward:5′-TTCTGGCCTGGAGGCTATC-3′;
reverse:5′-TCAGGAAATTTGACTTTCCATTC-3′;
human CXCR4:
forward: 5′-TTGTCATCACGCTTCCCTTCT-3′;
reverse: 5′-CATGGACTGCCTTGCATAGGA -3′
murine ZEB1:
forward: 5′-AGGTGATCCAGCCAAACG-3′
reverse: 5′-GGTGGCGTGGAGTCAGAG-3′
murine TP53:
forward: 5′-CAGTCTGGGACAGCCAAGTC-3′;
reverse: 5′-CAGCTGGCAGAATAGCTTATTGA-3′
murine p21:
forward: 5′-TCCACAGCGATATCCAGACA-3′;
reverse: 5′-GGACATCACAGGATTGGAC-3′
murine RPL13:
forward: 5′- CTCGGCCGTTCTCCTGTAT-3′;
reverse: 5′- GTGGAAGTGGGGCTTCAGTA-3′
Cell death quantification. The CellTox Green Cytotoxicity Assay (Promega,
Milan, Italy) was used to test cell death in CmPC cells treated with 1 μM DOXO for
increasing period of times (6, 24, 48 h, Figure 3a). This assay measures changes in
membrane integrity that occur as a result of cell death, using a dye that is excluded
from viable cells but preferentially stains the DNA from dead cells. When the dye
binds DNA released from cells, its fluorescence properties are substantially
enhanced. Therefore, the fluorescence signal produced by the interaction with DNA
from dead cells is proportional to cytotoxicity.
Apoptosis/necrosis in CmPC migration conditions (Figure 3b) were assessed by
using a cell death detection ELISA kit (Roche Diagnostics, Basel, Switzerland).
Quantification of histone-complexed DNA fragments (mono- and oligonucleosomes)
was performed by one-step sandwich immunoassay, measuring nucleosome-bound
DNA fragments by photometric analysis.
Migration assay. CmPC migration assay was evaluated in a 24-well modified
Boyden chamber as previously described.45 Briefly, CmPC were seeded in the
upper chamber of a modified Boyden chamber (Corning Corporation; 8-mm pore
size) and exposed or not (CTR) to DOXO 1 μM for 24 h under static conditions in
Ham’s F12 medium. The upper chamber was then placed in a 24-well culture dish
containing different stimuli: 500 μl of Ham’s F12 medium supplemented with 100 ng/
ml of SDF1 (R&D Systems) or 10% FBS (positive control) or Ham’s F12 medium
alone (negative control). After 16 h of incubation at 37 oC, 5% CO2, transmigrated
cells were counted. Non-migratory cells on the upper side of the membrane were
scraped off with wet cotton swabs. Cells present both in the lower chamber and on
the lower side of the filter were counted and considered as migrated cells. Each well
was washed with PBS with Ca2+/Mg2+ (Gibco, Life Technologies, Milan, Italy) to
remove debris and floating cells, then adherent cells were fixed for 15 min with 4%
paraformaldehyde (PFA) and washed 3 times. Cells were stained with 0.05%
Crystal Violet (Sigma-Aldrich) for 5 min and washed 3 times with PBS. To quantify
the cell number, the dye was solubilized with 10% acetic acid solution and the OD of
each well was quantified at 540 nm with Mithras LB 940 (Berthold Technologies,
Milan, Italy). The migration index (M.I.) was calculated by dividing the number of
cells migrated in presence of SDF1 or FBS by the number of cells migrated in
Ham’s F12 medium alone.
Lentiviral infection. Lentiviral supernatants were produced using standard
procedures. Briefly, HUVEC were infected for 2 h with lentiviral supernatants and
then were allowed to recover in complete fresh medium for additional 24 h.
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Afterwards, puromycin-containing medium (0.5 μg/ml, Sigma) was added to the
cells. MISSION shRNA lentiviral control and ZEB1-specific constructs were
purchased from Sigma. ZEB1 shRNA sequences were already tested for efficacy24
and used in this paper were: shRNAZEB1:
5′-CCGGGCTGTTGTTCTGCCAACAGTTCTCGAGAACTGTTGGCAGAACAACA
GCTTTTT-3′.
Flow cytometry. CmPC cultured in the indicated conditions were detached
using a non-enzymatic method, cells were resuspended in PBS containing 0.1%
BSA (Gibco) and 2 mM EDTA (Gibco) and incubated in the dark for 15 min with
suitable combinations of the monoclonal antibodies or isotype-matched control
monoclonal antibodies: CD29-PE, CD44-PE, CD73-PE, CD166-PE, CXCR4 APC
(BD Pharmingen). Samples were then washed with 1 ml of washing buffer and
centrifuged for 10 min at 400 × g at 4 °C to remove unbound antibodies. Cells were
resuspended in 250 μl of washing buffer and analyzed.
For Figure 5c, CmPC were incubated with Brilliant Violet 421(BV421)-conjugated
anti-CXCR4 antibody (Biolegend, San Diego CA) used at 1 μl in 30 μl final dilution for
15 min at RT. The CXCR4 signal (450 nm wavelenght) was plotted against an empty
channel of the FACSAria cell sorter (Beckton Dickinson, Franklin Lakes, NJ, USA)
receiving autofluorescence detected at 530 nm wavelenght (AF 530) to set up proper
positivity gates. Numbers indicate percentages of CXCR4-positive cells for the
indicated conditions. Flow cytometry data was analyzed by FlowJo software ver 9.9.5
(Treestar, Ashland, OR, USA).
Chromatin immunoprecipitation. Cells were incubated in 1% of formal-
dehyde for 10 min at 22 °C. The reaction was stopped by addition of glycine to a
final concentration of 0.125 M. Chromatin immunoprecipitations were performed as
previously described.46 Recovered DNA was analyzed by qRT-PCR. The following
primer sequences were used: from − 2097 bp to − 1997 bp forward, 5′-TGCCAAA
TCCTACCTTCTTCTG-3′; and reverse, 5′-CTTCCTTCGGAGGATGTAGC-3′; from
− 1680 bp to − 1572 bp forward, 5′-TTCCATCCACTTTAGCAAGGA-3′; and
reverse, 5′-CTCCCAGAGGCATTTCCTAA-3′; from -1029 bp to -910 bp forward,
5′-GGTCCTGCAGTTCGAGAGTT-3′; and reverse, 5′-CCAGGTGCGGTCTTAACC-3′;
from -324 bp to -210 bp forward, 5′-TGGCGTGGGTGTAGTGGG-3′; and reverse,
5′-TGATCCAGTTAACCCGGC-3′; from +735 bp to +871 bp forward, 5′-CACGAGGA
TGGCAAGAGAC-3′; and reverse, 5′-ACTTGTAGTGGGTAAAGAGAATGC-3′; from
+1402 bp to +1552 bp forward, 5′-TGCAAACCATTTTGCTCCGA-3′; and reverse,
5′-AAACTCCTCCCTGCACGATG-3′. We used a ChIP assay to examine ZEB1 and
Pol II occupancy at these sites, followed by quantitative real-time PCR (ChIP-qPCR).
Specific primers were used to amplify DNA regions encompassing ZEB1 consensus
sequences. To normalize ChIP-quantitative PCR data were analyzed with the Percent
Input Method. Percent input was calculated by 100 × 2(CtInput− CtEnriched). No antibody
values were subtracted.
Animal grouping and SDF1 administration. Experiments were
performed in accordance with national and international laws and policies (4D.L.
N.116, G.U., supplement 40, 18-2-1992; EEC Council Directive 86/609, OJ L
358,1,12-12-1987) and the guidelines indicated in the Declaration of Helsinki. The
protocol was approved by the University Committee on Animal Resources at the
University of Milan. All efforts were made to minimize animal suffering.
Preliminary tests were performed to evaluate the in vivo effect of SDF1
administration. First, based on the data available in the literature, two concentrations
of SDF1 (10 μg/kg and 40 μg/kg) were tested, identifying 10 μg/kg as the minimum
effective dose for the recruitment of CXCR4-positive cells from the bone marrow (data
not shown).
Female C57Bl/6 wild-type mice (Charles River Laboratories) aged 8 to 10 weeks
were randomly divided into three groups (Supplementary Fig. S3a). In the first group
(DOXO, n= 13), DOXO was administered in six equal intraperitoneal injections over a
period of 2 weeks (4 mg/kg each; cumulative dose, 24 mg/kg). In the second group
(DOXO+SDF1, n= 13), DOXO was administrated as in the first group and SDF1 was
administered in three equal intraperitoneal injections every 72 h, starting from the
second week of DOXO treatment (10 μg/kg each). In the third group (saline, n= 13),
control mice were treated with physiological saline in same manner as the regimens
for the DOXO group. Then, the percentage of bone marrow-mobilized CXCR4+ cells
following the systemic administration of SDF1 at a concentration of 10 μg/kg was
evaluated at different time points (6, 48 and 96 h). Results showed that the effect of
SDF1 administration on CXCR4+ cell mobilization was maintained 48 h after
treatment and was almost entirely absent at 96 h (Supplementary Fig. S3b). In order
to maximize the effect with the least possible number of injections, we decided to treat
mice with SDF1 every 72 h.
Echocardiography. Cardiac ultrasound studies were performed prior to and
3 weeks after treatment using the Vevo 2100 high-resolution imaging system
(VisualSonics) and a 40-MHz linear transducer with simultaneous electrocardio-
graphic recording. Analyses were performed on mice lightly anesthetized with 0.5 to
1% isoflurane (heart rate, 480–550 beats/min), 1 day before starting treatment
(baseline) and 21 days after drug administration (Figure 7). The anterior chest wall
was shaved, acoustic coupling gel was applied, and the transducer was placed
avoiding excessive pressure. Two-dimensional short-axis M-mode echocardiogra-
phy was performed at the level of the midpapillary muscle to measure LVESV and
LVEDV, LVAWd and LVEF.
Hemodynamics. LV performance was analyzed using a Millar pressure-volume
conductance catheter (SPR-839; Millar Instruments), as previously described.32
Briefly, at day 21, mice were anesthetized, the trachea was cannulated, and the
animal was connected to a positive-pressure volume-controlled rodent ventilator
(MiniVent). To measure the LVSP and maximal rate of pressure development
(+dP/dt) and maximal rate of pressure relation (-dP/dt), the catheter was introduced
through the right carotid artery into the ascending aorta and then into the LV cavity.
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